Roche's 138% Premium for Spark Shows M&A Arms Race for New Drugs

(Bloomberg) -- Shareholders in Spark Therapeutics Inc. woke up Monday to news of a windfall: Roche Holding AG agreed to buy the Philadelphia-based gene therapy company at a price that’s more than d...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.